Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application
Executive Summary
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
You may also be interested in...
Brazil Approves First Generic Version Of Sovaldi
Brazil’s first generic version of Sovaldi for hepatitis C is approved.
Argentina Rejects Key Sofosbuvir Patent Application
Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).
Argentina Rejects Key Sofosbuvir Patent Application
Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).